Coadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR) to levodopa, levodopa-induced postsynaptic pharmacodynamic mechanisms and molecular changes in hemiparkinsonian rats. 6-Hydroxydopamine-unilaterally lesioned rats were treated with levodopa (25 mg/kg) + vehicle; levodopa + entacapone (30 mg/kg) or saline, twice daily for 22 days. The LDR and the apomorphine-induced rotations were measured. In situ hybridization was performed measuring the expression of striatal preproenkephalin, preprodynorphin and dopamine D-3 receptor mRNAs, subthalamic cytochrome oxidase mRNA and nigral glutamic acid decarboxylase mRNA. Entacapone potentiated the LDR but did not modify either the apomorphine-induced rotational behavior or the molecular changes. Our results suggest that the effects of entacapone on levodopainduced motor response are not mediated by postsynaptic mechanisms and that administration of entacapone is not able to normalize the molecular alterations induced by levodopa in the basal ganglia.
Introduction
Under physiological circumstances, extra-synaptic striatal dopamine (DA) levels are relatively constant and DA receptors are stimulated in a relatively continuous manner (Abercrombie et al. 1990; Floresco et al. 2003; Venton et al. 2003) . In Parkinson's disease (PD), there is a loss of dopaminergic neurons and terminals and striatal DA levels are increasingly dependent on the peripheral availability of levodopa (Abercrombie et al. 1990; Miller and Abercrombie 1999; De la Fuente-Fernández et al. 2004) . Therefore, in advanced PD the fluctuations in plasma levels of short-acting dopaminergic agents, such as levodopa, lead to alternating high and low levels of activation of striatal DA receptors. This "pulsatile" pattern of receptor stimulation is a function of both, disease severity (Bédard et al. 1986; Pearce et al. 1998 Pearce et al. , 2001 Jenner 2000) and the short half-life of the dopaminergic agent employed (Bédard et al. 1986; Nutt 1990; Pearce et al. 1998; Olanow and Obeso 2000; Olanow et al. 2006) . Sustained evidence has been accumulated indicating that levodopa-related motor complications in PD are associated with non-physiological, intermittent or pulsatile stimulation of striatal DA receptors (Chase et al. 1989 (Chase et al. , 1994 Juncos et al. 1989; Blanchet et al. 1995; Grondin et al. 1996; Stocchi and Olanow 2004; Olanow et al. 2006; Fabbrini et al. 2007 ).
This concept suggests that a more continuous stimulation of DA receptors may ameliorate or even reduce the development of motor complications. The former has been shown in PD (Quinn et al. 1984; Obeso et al. 1986; Mouradian et al. 1990; Nutt 1990; Olanow et al. 2006; Nyholm 2007 ) and the latter in experimental parkinsonism (Bédard et al. 1986; Blanchet et al. 1995; Grondin et al. 1996; Pearce et al. 1998; Maratos et al. 2001; Jenner 2004; Smith et al. 2005; Nyholm 2007 ). The concept of continuous dopaminergic stimulation (CDS) is supported by a wealth of experimental data showing that the dopaminergic system exerts a dual (tonic and phasic) effect on the striatum (Grace 1991; Floresco et al. 2003) . In patients with PD, clinical pharmacological studies also support the therapeutical concept of CDS (Chase et al. 1989 , Obeso et al. 1994 , 2000 Olanow and Obeso 2000; Olanow et al., 2006) .
There is evidence suggesting that pulsatile striatal stimulation induces postsynaptic pharmacodynamic mechanisms which result in altered regulation of striatal genes and proteins, which ultimately leads to abnormal neuronal firing patterns in the striatopallidal circuitries (Herrero et al. 1995; Jolkkonen et al. 1995; Morissette et al. 1997 Morissette et al. , 1999 Olanow and Obeso 2000; Aubert et al. 2005; Gardoni et al. 2006; Bychkov et al. 2007 ). In more detail, chronic levodopa or dopamine agonist treatment elevates the expression of the striatal enkephalin precursor preproenkephalin (PPE), the opioid peptide expressed in the striatal neurons that project to the pars externa of the Neurobiology of Disease 32 (2008) 340-348 
